CALQUENCE also maintained efficacy and a sustained safety profile at four years for previously treated patients in ASCEND trial WILMINGTON, Del.--(BUSINESS WIRE)--Updated results from the ELEVATE-TN Phase III trial showed ...
Mavacamten is a first-in-class, investigational cardiac myosin inhibitor being developed by Bristol Myers Squibb Study met all primary and secondary endpoints and patients receiving mavacamten demonstrated improvement in key cardiac ...
MOSCOW, Feb. 14, 2022 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund), R-Pharm group and AstraZeneca announce interim results of phase II clinical trials to evaluate ...
The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with ...
Copyright © 2015 - 2021 Lifecarenews.in
